Loss of ALCAM expression is linked to adverse phenotype and poor prognosis in breast cancer: A TMA-based immunohistochemical study on 2,197 breast cancer patients

  • Authors:
    • Eike Burandt
    • Tanaz Bari Noubar
    • Annette Lebeau
    • Sarah  Minner
    • Christoph Burdelski
    • Fritz  Jänicke
    • Vollkmar  Müller
    • Luigi  Terracciano
    • Ronald  Simon
    • Guido Sauter
    • Waldemar  Wilczak
    • Patrick Lebok
  • View Affiliations

  • Published online on: October 1, 2014     https://doi.org/10.3892/or.2014.3523
  • Pages: 2628-2634
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Activated leukocyte cell adhesion molecule (ALCAM) is a membranous cell adhesion protein that is often expressed in breast cancer. Data on the prognostic impact of ALCAM expression is highly controversial in this cancer. To evaluate the clinical impact of ALCAM expression in a sufficiently large patient cohort, we utilized a tissue microarray (TMA) containing more than 2,100 primary breast cancers with clinical follow-up data by immunohistochemistry. TMA spots containing normal breast epithelium showed moderate to strong membranous ALCAM staining. ALCAM staining was strong in 66.2%, moderate in 10.9%, weak in 11.1% and absent in 11.8% of 1,778 (80.9%) interpretable breast cancer tissue spots. Decreased ALCAM expression was significantly associated with advanced tumor size (p=0.0017), unfavorable tumor grade (p<0.0001), negative ER and PR status (p<0.0001 each) as well as high Ki67 labeling index (p<0.0001). Cancers with ACLAM expression loss had a significantly poorer overall (p<0.0001) and disease-specific survival (p=0.0088). This association also held true in the subset of nodal positive cancers (p<0.0001). In conclusion, these data demonstrate that ALCAM is generally expressed in normal and cancerous breast epithelium and that a marked reduction of ALCAM expression characterizes a subset of breast cancer patients with adverse tumor characteristics and unfavorable clinical outcome.
View Figures
View References

Related Articles

Journal Cover

December-2014
Volume 32 Issue 6

Print ISSN: 1021-335X
Online ISSN:1791-2431

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Burandt E, Bari Noubar T, Lebeau A, Minner S, Burdelski C, Jänicke F, Müller V, Terracciano L, Simon R, Sauter G, Sauter G, et al: Loss of ALCAM expression is linked to adverse phenotype and poor prognosis in breast cancer: A TMA-based immunohistochemical study on 2,197 breast cancer patients. Oncol Rep 32: 2628-2634, 2014
APA
Burandt, E., Bari Noubar, T., Lebeau, A., Minner, S., Burdelski, C., Jänicke, F. ... Lebok, P. (2014). Loss of ALCAM expression is linked to adverse phenotype and poor prognosis in breast cancer: A TMA-based immunohistochemical study on 2,197 breast cancer patients. Oncology Reports, 32, 2628-2634. https://doi.org/10.3892/or.2014.3523
MLA
Burandt, E., Bari Noubar, T., Lebeau, A., Minner, S., Burdelski, C., Jänicke, F., Müller, V., Terracciano, L., Simon, R., Sauter, G., Wilczak, W., Lebok, P."Loss of ALCAM expression is linked to adverse phenotype and poor prognosis in breast cancer: A TMA-based immunohistochemical study on 2,197 breast cancer patients". Oncology Reports 32.6 (2014): 2628-2634.
Chicago
Burandt, E., Bari Noubar, T., Lebeau, A., Minner, S., Burdelski, C., Jänicke, F., Müller, V., Terracciano, L., Simon, R., Sauter, G., Wilczak, W., Lebok, P."Loss of ALCAM expression is linked to adverse phenotype and poor prognosis in breast cancer: A TMA-based immunohistochemical study on 2,197 breast cancer patients". Oncology Reports 32, no. 6 (2014): 2628-2634. https://doi.org/10.3892/or.2014.3523